Search Immortality Topics:

Page 12«..11121314..2030..»


Category Archives: Pharmacogenomics

Product Portfolio Analysis and Technological Development of Pharmacogenomics Market during the forecasted period – TechnoWeekly

The Pharmacogenomics Market research report recently presentedby Prophecy Market Insights which provides reliable and sincere insights related to the various segments and sub-segments of the market. The market study throws light on the various factors that are projected to impact the overall dynamics of the Pharmacogenomics market over the forecast period (2019-2029).

Influences of the market report:

An executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Pharmacogenomics market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/244

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Stakeholders Benefit:

Segmentation Overview:

The Pharmacogenomics research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Pharmacogenomics market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/244

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Highlights of the Report

Complete access to COVID-19 Impact on the Pharmacogenomics market dynamics, key regions, market size, growth rate and forecast to 2029

The report on the Pharmacogenomics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Some important Questions Answered in Pharmacogenomics Market Report are:

PharmacogenomicsMarket by Top Manufacturers:

Thermo Fisher Scientific Inc., Qiagen N.V., F.Hoffmann-La Roche AG, Abbot Laboratories, Diatech Pharmacogenetics, and Assurex Health Inc.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/244

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

See the rest here:
Product Portfolio Analysis and Technological Development of Pharmacogenomics Market during the forecasted period - TechnoWeekly

Posted in Pharmacogenomics | Comments Off on Product Portfolio Analysis and Technological Development of Pharmacogenomics Market during the forecasted period – TechnoWeekly

Drug Discovery Technologies Industry Market including top key players Luminex Corporation, Bayer Healthcare AG, Novartis AG – PRnews Leader

Drug Discovery Technologies Industry Market Forecast 2029: Revenue, Size & Growth

Global Drug Discovery Technologies Industry MarketForecast till 2029research includes reliable economic, international, and country-level forecasts and analysis. It offers a holistic view of the competitive market and thorough analyses of the supply chain to help companies identify closely significant trends in the company practices seen in the sector. Major Companies listed in this Reports areLuminex Corporation, Bayer Healthcare AG, Novartis AG, Agilent Technologies, Inc, Affymetrix Inc., Astrazeneca plc, Albany Molecular Research Inc., GE Healthcare Ltd., Abbott Laboratories, Inc., Arqule Inc..

Free Sample Report & Pie Charts Available@jcmarketresearch.com/report-details/1139660/sample

Regional Breakout for Drug Discovery Technologies Industry Market: North America XXX million $, Europe XXX million $, Asia XXX million $ & Rest of World.

OverviewDrug Discovery Technologies Industry Market including Types & Application:

North America:United States, Canada, and MexicoSouth & Central America:Argentina, Chile, and BrazilMiddle East & Africa:Saudi Arabia, UAE, Turkey, Egypt and South AfricaEurope:UK, France, Italy, Germany, Spain, and Russia

Application: Biopharmaceutical companies, Pharmaceutical companies, Research institutes, Biotech companies

Types:Biochips, High throughput screening, Pharmacogenomics, Genomics, Bioanalytical instruments, Bioinformatics, Nanotechnology, Others (RNAi, combinatorial chemistry)

Drug Discovery Technologies Industry Market Leading Competition:In this section, the report provides information on Competitive situations and trends including merger and acquisition and expansion, market shares of the top ten players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

Get Special Discount in Covid-19 @jcmarketresearch.com/report-details/1139660/discount

Research Methodology:

The market engineering process uses a top-down and bottom-up approach and several data triangulation methods to evaluate and validate the size of the entire market and other dependent sub-markets listed in Drug Discovery Technologies Industry report. Numerous qualitative and quantitative analyzes have been conducted in the market engineering process to list key information / insights. The major players in the market were identified through the second survey and the market rankings were determined through the first and second surveys.

Primary Research:

During the first survey, we interviewed various key sources of supply and demand to obtain qualitative and quantitative information related to Drug Discovery Technologies Industry report. Key supply sources include key industry participants, subject matter specialists from key companies, and consultants from several major companies and organizations active in the digital signage market.

Secondary Research:

The second study was conducted to obtain key information on the supply chain of the Drug Discovery Technologies Industry industry, the markets currency chain, pools of major companies, and market segmentation, with the lowest level, geographical market, and technology-oriented perspectives. Secondary data was collected and analyzed to reach the total market size, which was verified by the first survey.

Global Drug Discovery Technologies Industry Market Detailed study of each point:

TheDrug Discovery Technologies Industry Marketstudy offers a comprehensive overview of the current market and forecasts by 2020-2029 to help identify emerging business opportunities on which to capitalize.

The report provides an in-depth review of industry dynamics in Drug Discovery Technologies Industry, including existing and potential developments to represent prevailing consumer pockets of investment.

The report provides details concerning key drivers, constraints and opportunities and their effect on the Drug Discovery Technologies Industry market.

Industry players Luminex Corporation, Bayer Healthcare AG, Novartis AG, Agilent Technologies, Inc, Affymetrix Inc., Astrazeneca plc, Albany Molecular Research Inc., GE Healthcare Ltd., Abbott Laboratories, Inc., Arqule Inc. strategic analysis and industry position in the global Drug Discovery Technologies Industry market;

The report elaborates on the SWOT analysis and Porters Five Forces model.

The market-study value chain review gives a good view of the positions of the stakeholders.

GetCustomized Report Toc @:jcmarketresearch.com/report-details/1139660/enquiry

Major Highlights of Drug Discovery Technologies Industry Market in Covid-19 pandemic covered in report:

Market Competition by key manufacturers in the Drug Discovery Technologies Industry industry. Discussed Sourcing strategies, industrial chain information and downstream buyers data. Distributors and traders on Drug Discovery Technologies Industry marketing strategy analysis focusing on region wise needs in covid-19 pandemic. Vendors who are providing a wide range of product lines and intensifying the competitive scenario in Drug Discovery Technologies Industry covid-19 crisis. Also highlights of the key growth sectors of Drug Discovery Technologies Industry market and how they will perform in coming years.

Buy Full Copy Global Drug Discovery Technologies Industry Report 2029 @jcmarketresearch.com/checkout/1139660

** The demand is measured on the basis of the weighted average sale price (WASP), which requires the manufacturers taxes. The currency conversions that were used to construct this study were determined using a given annual average rate of currency exchange from 2020.

About Author:

JCMRglobal research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:https://jcmarketresearch.com/contact-us

JC MARKET RESEARCH

Mark Baxter (Head of Business Development)

Phone:+1 (925) 478-7203

Email:[emailprotected]

Connect with us at LinkedIn

http://www.jcmarketresearch.com

See the article here:
Drug Discovery Technologies Industry Market including top key players Luminex Corporation, Bayer Healthcare AG, Novartis AG - PRnews Leader

Posted in Pharmacogenomics | Comments Off on Drug Discovery Technologies Industry Market including top key players Luminex Corporation, Bayer Healthcare AG, Novartis AG – PRnews Leader

US Clinical Oncology Next Generation Sequencing (NGS) Market Projected to be Resilient During 2025 – Cheshire Media

U.S. Clinical Oncology Next Generation Sequencing (NGS)Market: Snapshot

With the advent of new technology, the potential that next generation sequencing (NGS) application holds in genetic counseling, disease management and treatment, and risk assessment is remarkable. From a clinical perspective, the technology can be applied to prenatal diagnosis, molecular diagnosis of genetic and infectious diseases, medical genetics and pharmacogenomics, carrier detection, cancer molecular diagnosis, and prognosis.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=47

In terms of technology, targeted sequencing and re-sequencing is a major contributor to the clinical oncology next generation sequencing market in the U.S. This technological segment will gain traction by enabling even higher throughput at reduced price per sample. Due to a decrease in the complexity of implementation, the use of whole genome sequencing (WGS) technology to make comparisons between tumor tissue and normal tissue is expected to witness a steep rise during the forecast period. In addition, researchers are of the opinion that through WSG everyone will be able to develop a personalized treatment plan. The segment is expected to grow further with the introduction of new tools such as NextSeq and MiniSeq platforms, which are likely to enhance the implement ability for a broad spectrum of research labs with varying sequencing needs.

Based on end user, the U.S. market for clinical oncology next generation sequencing is segmented into pharmaceutical and biotech entities, clinical research, academic research institutes, and hospitals and clinics. Owing to growing awareness regarding the benefits associated with the implementation of second-generation sequencing in academic and university-based research projects, academic institutes will hold a strong presence in the clinical oncology next generation sequencing market.

There are numerous players operating in the U.S. market. To hold their dominant position, many are banking on capitalizing data analysis requirements and need for more robust sequencing platforms through mergers and funding deals between major and minor players. A case in point would be Partek collaborating with Kennedy Krieger Institute. Together they have developed a commercial software for analyzing chromosomal abnormalities in diseases such as autism spectrum disorder, bipolar disorder, and schizophrenia.

U.S. Clinical Oncology Next Generation Sequencing (NGS)Market: Overview

With continued enhancement of new sequencing technology,next-generation sequencing(NGS) is being increasingly used in cancer genomics research. Also known as massively parallel sequencing, these days NGS is being leveraged in clinical oncology to provide improved tailored therapy for cancer. Next generation sequencing finds application in detecting rare forms of cancer mutations, uncovering familial cancer mutation carriers, and in providing molecular rationale for the exact targeted therapy. Hence, it is widely considered as a disruptive technology in the area of cancer treatment.

There have been many noteworthy achievements in the field of cancer genetics in the past couple of years on account of cutting-edge technologies and tanking costs of next-generation sequencing (NGS). The report by TMR Research offers key insights into the U.S. clinical oncology Next Generation Sequencing (NGS) market. It studies the degree of research and development in next generation sequencing for clinical oncology and furnishes crucial market figures from 2017 to 2025.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=47<ype=S

U.S. Clinical Oncology Next Generation Sequencing (NGS) Market: Trends and Opportunities

Next generation sequencing has a number of advantages over traditional sequencing. First is its ability to completely sequence every kind of mutations for a large number of genes in one test cost-effectively. However, challenges exist in leveraging NGS, especially with respect to the need for simpler assays, more flexible throughput, reduced turnaround time, and most importantly in analyzing and interpreting the data. Overall, continued efforts to apply NGS in clinical oncology will take us one step closer to personalized medicine.

In the U.S., the clinical oncology next generation sequencing market has been buoyed by the astute initiatives of the government in the field of research and development in oncology. For example, loans and grants have been liberally disbursed by the U.S. government and various funding bodies to bring down the gap between genomic sequence analysis platforms development and their use in oncology research. In the near future, the substantial increase in spending related to cancer in the U.S. is slated to further drive up the demand for second generation sequencing platforms for diagnostic monitoring and theranostics applications.

A major challenge to the next generation sequencing is the time taken to uncover insights from the copious amount of data generated after the genome is sequenced. While this benefits the cancer patients as its aids in accurately studying many genes simultaneously that may be relevant to the patients tumor by using only a small amount of tissue at a reasonable cost, it also accords innumerable opportunities to commercial service providers to come up with proper solutions in much less time.

Companies Mentioned in Report

To present an in-depth assessment of the competition prevailing in the U.S. market for clinical oncology next generation sequencing, the report profiles companies such as Roche, llumina Inc., Pacific Bioscience, Agilent Technologies, GATC Biotech Ag, Macrogen Inc., Oxford Nanopore Technologies Ltd, Foundation Medicine, Life technologies Corp, Exosome Diagnostics, CLC Bio, Paradigm, Perkin Elmer, Inc, Inc, Partek, Inc, GnuBIO, and Caris Life Sciences.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=47

About Us:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Continue reading here:
US Clinical Oncology Next Generation Sequencing (NGS) Market Projected to be Resilient During 2025 - Cheshire Media

Posted in Pharmacogenomics | Comments Off on US Clinical Oncology Next Generation Sequencing (NGS) Market Projected to be Resilient During 2025 – Cheshire Media

Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens – DocWire News

This article was originally published here

Patterns (N Y). 2020 Jul 2;1(5):100065. doi: 10.1016/j.patter.2020.100065. eCollection 2020 Aug 14.

ABSTRACT

High-throughput drug screens in cancer cell lines test compounds at low concentrations, thereby enabling the identification of drug-sensitivity biomarkers, while resistance biomarkers remain underexplored. Dissecting meaningful drug responses at high concentrations is challenging due to cytotoxicity, i.e., off-target effects, thus limiting resistance biomarker discovery to frequently mutated cancer genes. To address this, we interrogate subpopulations carrying sensitivity biomarkers and consecutively investigate unexpectedly resistant (UNRES) cell lines for unique genetic alterations that may drive resistance. By analyzing the GDSC and CTRP datasets, we find 53 and 35 UNRES cases, respectively. For 24 and 28 of them, we highlight putative resistance biomarkers. We find clinically relevant cases such as EGFRT790M mutation in NCI-H1975 or PTEN loss in NCI-H1650 cells, in lung adenocarcinoma treated with EGFR inhibitors. Interrogating the underpinnings of drug resistance with publicly available CRISPR phenotypic assays assists in prioritizing resistance drivers, offering hypotheses for drug combinations.

PMID:33205120 | PMC:PMC7660407 | DOI:10.1016/j.patter.2020.100065

See the original post here:
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens - DocWire News

Posted in Pharmacogenomics | Comments Off on Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens – DocWire News

Global Genomic Cancer Panel and Profiling Markets Report 2021-2025: The Market is Moving Out of a Specialized Niche and Going Mainstream -…

Dublin, Nov. 19, 2020 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail.

Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. And there is a lot of information to be had. But the COVID-19 Pandemic has impacted the market.

Comprehensive panels, genomic profiling, high-risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions.

Key Topics Covered:

Cancer Panel Market - Strategic Situation Analysis & COVID Update

1. Introduction and Market Definition 1.1 What are Cancer Gene Panels and Profiling? 1.2 The Sequencing Revolution 1.3 Market Definition 1.4 Methodology 1.5 A Spending Perspective on Clinical Laboratory Testing 1.5.1 An Historical Look at Clinical Testing

2. Market Overview 2.1 Players in a Dynamic Market 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer2.1.3 Instrumentation Supplier 2.1.4 Distributor and Reagent Supplier 2.1.5 Independent Testing Lab2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Office Labs 2.1.9 Audit Body 2.1.10 Certification Body2.2 Oncogenomics2.2.1 Carcinogenesis2.2.2 Chromosomes, Genes and Epigenetics 2.2.2.1 Chromosomes 2.2.2.2 Genes 2.2.2.3 Epigenetics 2.2.3 Cancer Genes 2.2.4 Germline vs Somatic 2.2.5 Gene Panels, Single Gene Assays and Multiplexing 2.2.6 Genomic Profiling 2.2.7 The Comprehensive Assay 2.2.8 Changing Clinical Role 2.2.9 The Cancer Screening Market Opportunity2.3 Cancer Management vs. Diagnosis 2.3.1 The Role of Risk Assessment 2.3.2 Diagnosis 2.3.3 Managing 2.3.4 Monitoring 2.4 Phases of Adoption - Looking into The Future 2.5 Structure of Industry Plays a Part 2.5.1 Hospital Testing Share 2.5.2 Economies of Scale2.5.2.1 Hospital vs. Central Lab 2.5.3 Physician Office Lab's 2.5.4 Physician's and POCT

3. Market Trends3.1 Factors Driving Growth3.1.1 Level of Care 3.1.2 Companion Dx 3.1.3 Immuno-oncology 3.1.4 Liability3.1.5 Aging Population3.2 Factors Limiting Growth3.2.1 State of knowledge3.2.2 Genetic Blizzard. 3.2.3 Protocol Resistance3.2.4 Regulation and coverage 3.3 Instrumentation and Automation 3.3.1 Instruments Key to Market Share 3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development3.4.1 Next Generation Sequencing Fuels a Revolution 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay

4. Cancer Panels & Profiles Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Cancer Gene Panels and Profiles

7. Global Cancer Gene Panels & Profiles Markets - By Type of Cancer 7.1 Comprehensive Panels & Profiles 7.2 Breast Cancer Gene Testing 7.3 Colorectal Cancer Gene Testing7.4 Gynecological Cancer Gene Testing 7.5 Blood Cancer Gene Testing 7.6 Prostate Cancer Gene Testing 7.7 Lung Cancer Gene Testing7.8 Other Cancer Gene Testing

8. Global Cancer Gene Testing Markets - Germline and Somatic 8.1 Global Market Somatic 7.3 Global Market Germline

9. Potential Market Opportunity Sizes 9.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal 9.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer 9.3 Potential Market Size - Cancer Diagnosis 9.4 Potential Market Size - Therapy Selection

Appendices

For more information about this report visit https://www.researchandmarkets.com/r/5bx3ai

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More:
Global Genomic Cancer Panel and Profiling Markets Report 2021-2025: The Market is Moving Out of a Specialized Niche and Going Mainstream -...

Posted in Pharmacogenomics | Comments Off on Global Genomic Cancer Panel and Profiling Markets Report 2021-2025: The Market is Moving Out of a Specialized Niche and Going Mainstream -…

Direct-to-Consumer Genetic Testing: Global Markets and Technologies – GlobeNewswire

New York, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Direct-to-Consumer Genetic Testing: Global Markets and Technologies" - https://www.reportlinker.com/p05987656/?utm_source=GNW

This report reviews the main DTC genetic testing technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR) and genotyping microarrays.

The report then discusses several of the significant large-scale population sequencing initiatives that are contributing to DTC genetic testing development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2019 through September 2020. Industry subsectors analyzed include ancestry, clinical health, recreational health, sequencing data-based blockchain, sequencing instrument, long-read sequencing, sequencing informatics and PCR.

The market for DTC genetic testing is analyzed in depth. The market is analyzed by test purpose (ancestry, health, lifestyle); by technology platform (PCR, genotyping arrays, sequencing); by delivery format (test kits, virtual tests); and by geography (North America, Europe, Asia/Pacific, RoW).

The ancestry market segment is analyzed by technology and by ethnicity (African, Asian, European, Latino, other). The health market segment is analyzed by technology and by disease category (cancer, cardiovascular, complex common, pharmacogenomics, rare diseases and other). The lifestyle market segment is analyzed by technology and by application (genetic relatedness, nutrigenomics, personal traits, weight management/fitness, other)

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

More than 55 companies in the DTC genetic testing industry are profiled in this report.

The analyst provides a summary of the main industry acquisitions and strategic alliances from January 2019 through September 2020, including key alliance trends.

Report Inludes: - 12 data tables and 39 additional tables - An overview of the global markets and technologies for direct to consumer (DTC) genetic testing - Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025 - Information on key genomic regions associated with genetic testing and description of instruments and technologies used for DTC genetic testing - Coverage of DNA sequencing; microarray; and software industries and description of the key initiatives in the genetic testing industry - Detailed analysis of the current market trends, market forecast and discussion of technological, regulatory and competitive elements as well as economic trends affecting the future marketplace for direct to consumer (DTC) genetic testing and impact analysis of COVID-19 on the market - Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry - Profiles of the key companies in the DTC testing industry, including Chendu 23Mofang Biotechnology Co. Ltd (23Mofand), Genetic Technologies Ltd, Illumina Inc., Myriad Genetics Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Inc.

Summary: Direct-to-consumer (DTC) genetic testing involves the analysis and interpretation of a persons genome. A consumer can access DTC genetic testing from a commercial company or from a health care provider.

DTC genetic testing has evolved in the past 10 years. Initially it focused on personal applications outside traditional health care, such as exploring ancestry and has trended toward interfacing with clinical care in non-traditional ways, such as partnerships between DTC companies with health systems.

Analysis of a customers genome helps to know about their ancestry inference, disease risks and other personal traits. Based on this, the main applications include ancestry, health and lifestyle.

Several factors are driving growth in the DTC genetic testing industry, including a shifting emphasis on health-related applications, the rise of personalized genomics and increasing convenience of ordering goods and services from virtual at-home settings. This latter trend has been accelerated by the COVID- 19 pandemic.

There is rising public awareness of DNA and its impact on health and genetic disorders, ancestry and lifestyle. These trends are having a favorable impact on the at-home genetic testing market. This report provides an in-depth analysis of the DTC genetic testing industryRead the full report: https://www.reportlinker.com/p05987656/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the rest here:
Direct-to-Consumer Genetic Testing: Global Markets and Technologies - GlobeNewswire

Posted in Pharmacogenomics | Comments Off on Direct-to-Consumer Genetic Testing: Global Markets and Technologies – GlobeNewswire